ICCAS was founded in 1956. ICCAS is a multi-disciplinary research institute dedicated to the basic research in broad fields of chemical sciences, and to the key developments of the innovative high technologies aiming to the imperative national needs and important strategic targets, as well as to the collaborative high-technology applications and transfers. ICCAS is one of China’s leading chemistry research institutions with high international reputation.

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Kenilworth, NJ.

Intra-Cellular Therapies (ITI) is developing novel drugs for the treatment of neuropsychiatric and neurologic diseases and other disorders of the Central Nervous System (CNS). We combine the efforts of medicinal chemists, pharmacologists, biologists and clinical development scientists into a vibrant team that translates world-class research expertise into novel drugs. The company's lead product, ITI-007 is a novel first-in-class 5-HT2A antagonist, Dopamine receptor phosphoprotein modulator (DPPM) designed to treat multiple deficits in patients with schizophrenia while lacking the side-effects of existing antipsychotic drugs. ITI has also developed a state of the art technology platform, called CNSProfile™ that is capable of generating a unique molecular signature for drug compounds. This profile provides us with a proprietary window into the intracellular action of CNS drugs or drug candidates. We use this tool to fingerprint the intracellular molecular actions of existing drugs and to drive our internal drug discovery and development. Our technology has also enabled the company to examine the toxic effects of brain damaging nerve agents, and as a result, we are involved in collaborative efforts with several military and contract organizations to develop antidotes to chemical warfare agents. Based upon our understanding of the Central Nervous System we have discovered novel drug candidates with promise for treating the panoply of symptoms associated with the transition from peri-menopausal to post-menopausal states. Intra-Cellular Therapies was founded in 2002 by Drs. Paul Greengard, Sharon Mates and Allen Fienberg. The company is headquartered in New York City.

Pomerai (Changzhou) Biotechnology Co., Ltd., established on 2020-06-29, Business scope includes licensed projects:Sales of special products for computer information system security(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,Specific business projects are subject to approval results) General project:Information Technology Consulting Services;Intellectual Property Services;internet data service;Information system operation and maintenance services;Wholesale of computer software, hardware and auxiliary equipment;Cloud Computing Equipment Sales;Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Internet of Things Technology Services;Biochemical product technology research and development;R&D of industrial enzyme preparations;Specialty Chemicals Sales(Free of Hazardous Chemicals);Engineering and Technology Research and Experimental Development;Artificial intelligence basic resources and technology platform;Development of Human Gene Diagnosis and Therapy Technology;Fermentation process optimization technology research and development;Medical Research and Experimental Development;Chemical product sales(No licensed chemical products);Experimental analysis instrument sales;Natural science research and experimental development;Extraction of marine bioactive substances,purification,Synthesis technology research and development;Agricultural Science Research and Experimental Development;Research and development of biopesticide technology;software sales;Blockchain technology related software and services;software development;Artificial intelligence basic software development;Artificial intelligence application software development;Software outsourcing service;Artificial intelligence theory and algorithm software development;Retailing of computer software, hardware and auxiliary equipment;Sales of industrial control computers and systems;Data processing and storage support services(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)

The Korea Atomic Energy Research Institute (KAERI) in Daejeon, South Korea was established in 1959 as the sole professional research-oriented institute for nuclear power in South Korea, and has rapidly built a reputation for research and development in various fields. In 1995 KAERI designed and constructed the nation's first multipurpose research reactor, HANARO based on the Canadian MAPLE design. KAERI is dedicated to finding a wide range of uses for atomic energy. As examples, KAERI developed the world's first radiopharmaceutical "Milican injection" for treating liver cancer.

Celltech R&D Ltd., a subsidiary of UCB SA, is a British company located in Slough that engages in drug discovery and development. It was founded in 1980.

UbiVac is a clinical-stage biotechnology company engaged in the research and development of therapeutic vaccines to combat cancer. Founded in Portland, OR in 2005 as a spinout of the Robert W. Franz Cancer Research Center within the Earle A. Chiles Research Institute, at Providence Portland Medical Center, UbiVac continues to build upon the groundbreaking research being developed in the region.

Shenzhen Letu Bio-Pharmaceutical Co., Ltd., established on 2016-07-15, Business scope includes general business items:medicine,medical instruments,Health products,cosmetic,Research and development of raw materials and preparations for special-purpose formula foods,Technology transfer and related technical consultation and services;Development and application of stem cell and cell immunotherapy technology(Does not contain collection of human genetic resources,collect,Trading and Other Restricted Items);Research and development of biopharmaceutical products,transfer of own technology,Provide relevant technical services and technical consultation;Technical development of biological products,Technical consulting and technology transfer.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments),The licensing program is:collection of stem cells,storage;Collection of immune cells,storage;Building cell and tissue banks(None of the above excludes the collection of human genetic resources,collect,Trading and Other Restricted Items).

Henan Ruida Pharmaceutical Technology Co., Ltd., established on 2014-11-06, Business scope includes general items:Medical Research and Experimental Development;Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;software development;Information system integration service;Big data service;internet data service;Sales of Class I Medical Devices;Sales of Class II Medical Devices;Healthy food(prepackaged)Sales;Food import and export;Specialty Chemicals Sales(Free of Hazardous Chemicals);Instrument sales;Disinfectant sales(Free of Hazardous Chemicals);Business Management Consulting;marketing planning;market survey(Does not include foreign investigations);Health Consulting Services(Does not include medical services);Digital Content Production Services(Does not include publishing);Computer and communication equipment rental;Retailing of computer software, hardware and auxiliary equipment;Cosmetics Wholesale;Cosmetics Retail;General merchandise sales(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)licensed items:Drug Wholesale;Drug retail;Class III medical device business;food sales;pharmaceutical production;Pharmaceutical commissioned production(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,The specific business items are subject to the approval documents or licenses of relevant departments)

Roche Glycart AG discovers and develops drugs. It is active in the research and development of new potent antibody-based products for the treatment of unmet clinical needs such as cancer. It uses its proprietary set of technologies to endow therapeutic antibodies. The company has developed glycoengineering technology (GlycoMAb) to boost a natural mechanism of action of therapeutic antibodies developed to mediate target cell killing. The company was founded in 2000 and is headquartered in Zurich, Switzerland.

ImmunoCellular Therapeutics, Ltd. is a clinical-stage pharmaceutical company, focused on the development of therapeutics and delivery technologies for the treatment of inflammatory conditions and ocular diseases. Its lead clinical asset is EOM613 solution, a peptide nucleic-acid solution with anti-inflammatory and pro-inflammatory effects on cytokines and chemokines for the treatment of cancer cachexia and rheumatoid arthritis. The company also develops EOM 147, an investigational, broad-spectrum aminosterol with an intracellular mechanism for the treatment of chronic and debilitating retinal diseases. The company was founded on March 20, 1987 and is headquartered in Montvale, NJ.

Anhui Huien Biotechnology Co., Ltd., established on 2013-05-17, Business scope includes cell engineering,Development and sales of detection technology for products related to genetic engineering and protein engineering;cell therapy technology,Development and service of protein therapy and gene detection technology;cell engineering,Technical achievements transfer service of genetic engineering and protein engineering,technical consulting;cell collection,Detection and storage service;Production of cellular cosmetics,Technology development and sales;Research in Biological Sciences and Technology,transfer,Consulting and Services;Development of cell therapy drugs and biomedical technologies;one type,Class II,Research and development of three types of medical devices;Healthy food,Technical development and sales of healthcare products;Conference Services;Biomedical Technology Services.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Wuxi Fuze Pharmaceutical Co., Ltd., established on 2016-07-15, Business scope includes biomedicine,Healthy food,cosmetic,medical instruments,Pharmaceutical Intermediates(Does not contain dangerous goods)technology development,technical consulting,Technical Services,technology transfer;Pre-packaged food,medical instruments,Pharmaceutical intermediates and chemical products(Free of Hazardous Chemicals),sales of cosmetics;Self-operated and agent import and export business of various commodities and technologies(Except for commodities and technologies that the state restricts enterprises to operate or prohibits import and export).(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Shandong Kaiti Biological Products Co., Ltd., established on 2018-10-22, Business scope includes biological products(In addition to vaccines)technology development,technology transfer,technical consulting,Technical Services;wholesale,retail:Biological product(In addition to vaccines),biological reagent;Import and export business(Excluding state trade management goods)and other legal,regulations,Items that are not prohibited by the State Council's decision and other regulations and do not require a business license.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Kunming Institute of Zoology (KIZ) (中国科学院昆明动物研究所), one of the 20 biological institutes under the Chinese Academy of Sciences (CAS), is one of China's first class zoological research institutes, located in Kunming, Yunnan province. The Institute has access to the unique and diversified animal resources of the Eastern Himalayas as well as a wide variety of the species from across Southeast Asia, the southern parts of Yunnan province being part of the Indo-Burma biodiversity hotspot. KIZ focuses on life science research, with research groups including systematic zoology, conservation biology, cytology, molecular biology, genome evolution, reproductive and developmental biology, neurobiology, immunological biology on important virus disease, zoological toxicology and primate biology.

Part of Southern Medical University, Zhujiang Hospital of Southern Medical University is a company headquartered in Guangzhou, China, that operates hospital.

Nantong WuXi PharmaTech Co., Ltd., established on 2018-04-26, Business scope includes medical technology,Biological Technology,Technology development in the field of detection technology,technology transfer,Technical Consulting and Technical Services(Except for those prohibited by the state for foreign investment);General chemical products(Removal of hazardous chemicals,Monitor Chemicals,firecrackers,civilian explosives,precursor chemicals)Sales,Operate the export business of the company's self-produced products and the import and export business of raw and auxiliary materials required by the company(Commodities that do not involve state trade management,Products involving quota license management,Apply in accordance with relevant national regulations).(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)